Apellis Pharmaceuticals

$47.60
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.25 (-0.52%) Today

$0.00 (0.00%) As of 11:00 PM UTC after-hours

Why Robinhood?

You can buy or sell APLS and other stocks, options, and ETFs commission-free!

About APLS

Apellis Pharmaceuticals, Inc. Common Stock, also called Apellis Pharmaceuticals, is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA. The listed name for APLS is Apellis Pharmaceuticals, Inc. Common Stock.

CEO

Cedric Francois

Employees

235

Headquarters

Waltham, Massachusetts

Founded

2009

Market Cap

3.61B

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

794.13K

High Today

$49.42

Low Today

$46.86

Open Price

$48.34

Volume

722.58K

52 Week High

$49.42

52 Week Low

$16.85

Collections

Analyst Ratings

79%

of 14 ratings

Buy

79%

Hold

21%

Sell

APLS Earnings

-$2.29

-$1.53

-$0.76

$0.00

Q1 FY19

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Feb 25, Pre-Market